The results of the present study extend the current knowledge of muscle pathophysiology in the two diseases, suggesting that Cpt1b may represent a new potential therapeutic target for the treatment of muscle atrophy that generally accompanies the onset of osteoarthritis and osteoporosis in elderly people. This evidence concerns the gene CPT1B and osteoporosis.